



A guide for
Design Teams

AI empowered **E-detailing + CLM** Tablet interface

See how it works

The given example in this
Content Design Guideline
is “Revotone Detailaid”
created by Revo Team



Your edetailaid content:

Slides

Tags


References

Videos



REVO Home





Product folders





Revotone[®] Pedia
Multivitamin Supplement Fortified with Vit D & Calcium for your toddler

Revotone[®] Pedia 16 Slides

Revotone[®] Maternity
Multivitamin Supplement Fortified with Folic Acid for baby development

Product Folder

Revotone[®] Maternity 13 Slides

Revotone[®] Adult
Multivitamin Supplement Fortified with Omega 3, 6, 9 complex

Revotone[®] Adult 14 Slides



Back button



Logo



Specs:

Naming: ProductName_Logo.Png

File measurements: 407_{px} x 204_{px}

Format: .png

Color Mode: RGB



Detail aids

Specs:

Naming: PresentationName_Cover.Png

File measurements: 619px x 509px

Format: .png

Color Mode: RGB



Revotone[®] Pedia

Multivitamin Supplement Fortified with Vit D & Calcium for your toddler



Detailing Mode





Swipe horizontally to change slide



Revotone[®] Pedia

Fortified with Vit D & Calcium for your toddler


REVOTONE[®] - Pedia

Fortified with Vit D & Calcium for your toddler



Haemoglobin (g/dL) – PP analysis²

Revo tone[®]
Mega Multi Multivitamin
Supplement A,C,E & B complex



P values are not significant at either 4 or 8 weeks.

Study Design



**Double blind multi centre 12 months study on 200 patients
age range 20 to 40, half of them show improvement**


Calcium as a nutrient is most commonly associated with the formation and metabolism of bone. Over 99 percent of total body calcium is found as calcium hydroxyapatite ($\text{Ca}_{10}[\text{PO}_4]_6[\text{OH}]_2$) in bones and teeth

Bottomless Slide





Presentation slide specs



Naming: PresentationName_SlideNumber.jpg

Measurements in pixels: 1920 x 1200 px

Resolution: 72 dpi

File size: less than 1 Mb


Format: .jpg

Color Mode: RGB

Bottomless slide specs



Use a longer form...



Naming: PresentationName_PrimarySlideNumber_1.jpg

Naming: PresentationName_PrimarySlideNumber_2.jpg

Measurements in pixels: 1920 x 1200 px

Resolution: 72 dpi

File size: less than 1 Mb

Format: .jpg


Color Mode: RGB

Safety & Efficacy

Revotone proven to be safe and effective in 1st trimester ⁵

Revotone®
Mega Multi Multivitamin
Supplement A,C,E & B complex

Percentages of live births



Group1

98.9%



Group2

94.7%

Tap to animate slide



Animated slides



Optional



Auto animate



Animate on click

To be provided: open AI file for the slide to be animated.

Action allowed: (2 actions per slide limit)

Auto animate — The slide start animation upon start

Animate on click — Click a specific item for the next animation to happen.



You can use a mixed action or 2 actions animate on click.



Presentation Slides



RESET ORDER

quick view to access slides

USP

Efficacy


Fetus Development

Diabetes


Tolerability

Dosage


Flash call




1-Revotone_001




2-Revotone_002



2-Revotone_003




4-Revotone_004



5-Revotone_005



6-Revotone_006



7-Revotone_007



8-Revotone_008

Efficacy

Parameter / Age	Hemoglobin below: g/dL	Hematocrit below: %
6 months to 5 years	11	33
5 - 11 years	11.5	34
12 - 13 years	12	36



Slide tags mapping



Revotone_Slide Tags.rtf	
Slide 8 - 10	----> efficacy
Slide 11	----> Dosage
Slide 16	----> cognitive decline
Slide 17	----> Osteoporosis
Slide 18	----> Diabetes
Slide 19	----> Dosage
Slide 25	----> safety & efficacy
Slide 26	----> tolerability
Slide 27_1	----> fetus development
Slide 28	----> Dosage
Slide 29	----> USP
Slide 30	----> ref.



Slide Tags: Mapping slides with its topic “Efficacy, Dosage, Tolerability....”





You can add multiple tags per slide




Presentation Slides




Mechanism of action


Patient story


Expert opinion

Don't limit yourself

File Size: Each video file shouldn't exceed 50MB
File Format: mp4



NIH Public Access Author Manuscript

Mayo Clin Proc. Author manuscript; available in PMC 2009 September 1.

Published in final edited form as:

Mayo Clin Proc. 2008 September ; 83(9): 1032–1045.

Bisphosphonates: Mechanism of Action and Role in Clinical Practice

Matthew T. Drake, MD, PhD, Bart L. Clarke, MD, and Sundeep Khosla, MD

From the Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN

Abstract

Bisphosphonates are primary agents in the current pharmacological arsenal against osteoclast-mediated bone loss due to osteoporosis, Paget disease of bone, malignancies metastatic to bone, multiple myeloma, and hypercalcemia of malignancy. In addition to currently approved uses, bisphosphonates are commonly prescribed for prevention and treatment of a variety of other skeletal conditions, such as low bone density and osteogenesis imperfecta. However, the recent recognition that bisphosphonate use is associated with pathologic conditions including osteonecrosis of the jaw has sharpened the level of scrutiny of the current widespread use of bisphosphonate therapy. Using the key words *bisphosphonate* and *clinical practice* in a PubMed literature search from January 1, 1998, to May 1, 2008, we review current understanding of the mechanisms by which bisphosphonates exert their effects on osteoclasts, discuss the role of bisphosphonates in clinical practice, and highlight some areas of concern associated with bisphosphonate use.

Since their introduction to clinical practice more than 3 decades ago, bisphosphonates have

Published in final edited form as:
Mayo Clin Proc. 2008 September ; 83(9): 1032–1045.

Bisphosphonates: Mechanism of Action and Role in Clinical Practice

Matthew T. Drake, MD, PhD, Bart L. Clarke, MD, and Sundeep Khosla, MD
From the Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN

Abstract

Bisphosphonates are primary agents in the current pharmacological arsenal against osteoclast-mediated bone loss due to osteoporosis, Paget disease of bone, malignancies metastatic to bone, multiple myeloma, and hypercalcemia of malignancy. In addition to currently approved uses, bisphosphonates are commonly prescribed for prevention and treatment of a variety of other skeletal conditions, such as low bone density and osteogenesis imperfecta. However, the recent recognition that bisphosphonate use is associated with pathologic conditions including osteonecrosis of the jaw has sharpened the level of scrutiny of the current widespread use of bisphosphonate therapy. Using the key words *bisphosphonate* and *clinical practice* in a PubMed literature search from January 1, 1998, to May 1, 2008, we review current understanding of the mechanisms by which bisphosphonates exert their effects on osteoclasts, discuss the role of bisphosphonates in clinical practice, and highlight some areas of concern associated with bisphosphonate use.

Since their introduction to clinical practice more than 3 decades ago, bisphosphonates have been increasingly used for an array of skeletal disorders. Bisphosphonates are now used to treat such varied conditions as heritable skeletal disorders in children, postmenopausal and

4. Omega-3_fatty_acids___University_of_Marylan_Medical_Center

OVERVIEW

The Egyptian Osteoporosis Prevention Society (EOPS) was founded in 1999. The main objective of the society is to deliver awareness and prevention programmes for public and patients, by arranging sessions, educational support, and public events. As well physician education is carried out through annual meetings and workshops providing up-dates of diagnosis and treatment of osteoporosis and osteoarthritis.

In 2010 EOPS provided education programmes to junior physicians, including information on the latest and most useful facts on osteoporosis. The second course also covered:

- Osteoporosis In Children and Adolescents
- Bone Markers
- Bone Densitometry: The ideal detector for osteoporosis
- Glucocorticoid-Induced Osteoporosis

EOPS is currently involved in a large project – Prevalence of Osteoporosis Among the Egyptian Population - targeting a specific age group. As well, two other studies are in progress - Osteoporotic Hip Fractures, and Prevalence of Osteoarthritis and Osteoporosis in Rheumatoid Patients.

Furthermore, EOPS provides targeted suburban awareness programmes with recent sessions at Menia, and Luxor. As part of a three-year activity plan, these events will continue throughout Egypt's five main government areas. The EOPS website, www.egyptianops.org, was re-launched two years ago, with regular updates planned.

KEY FINDINGS

The present population in Egypt is estimated to be 80 million, of this 15% (12 million) is 50 years of age or over and 2.5% (2 million) is 70 or over. By 2050, it is estimated that 29% (40 million) of the population will be 50 or over and 8.4% (11 million) will be 70 or over while the total population will increase to 138 million (fig 1).

EPIDEMIOLOGY

Osteoporosis is a very old disease, as it was already present in ancient Egyptians (2687-2191 BC)! Zaki et al examined 74 skeletons and performed a DNA scan on these ancient Egyptians.


TABLE 1 Osteoporosis and osteopenia prevalence in ancient Egyptians

OSTEOPENIA (%) OSTEOPOROSIS (%)

2. Iron_deficiency_anemia_treatment_response_to_iron_therapy__analysis_of_five_randomized_controlled_trials


Since their introduction to clinical practice more than 3 decades ago, bisphosphonates have been increasingly used for an array of skeletal disorders. Bisphosphonates are now used to treat such varied conditions as heritable skeletal disorders in children, postmenopausal and glucocorticoid-induced osteoporosis (GIO), and bone metastases in patients with malignancies. Bisphosphonates can offer substantial clinical benefit in conditions in which an imbalance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption underlies disease pathology; however, the more recently recognized association of bisphosphonate use with pathologic conditions, including low bone turnover states with resultant pathologic fractures, osteonecrosis of the jaw (ONJ), and an increased incidence of atrial fibrillation, has brought increased scrutiny to the current broad use of bisphosphonate therapy.

PubMed literature from January 1, 1998, to May 1, 2008, was reviewed using *bisphosphonate* and *clinical practice* as search terms. Additional articles not obtained in the primary search were identified by assessment of literature referenced in the reviewed articles. We present data on the development of bisphosphonates as therapeutic agents, the proposed mechanisms by which these agents exert their effects, and the current roles for bisphosphonate therapy in clinical practice. Additionally, we address some areas of concern for clinicians and draw attention to some currently unresolved issues associated with bisphosphonate use.





References to be provided as follows



1- Vitamin D and Bone Health; Potential Mechanisms



2- Iron deficiency anemia treatment response to oral iron therapy



3- Overview of Calcium - Dietary Reference Intakes for Calcium and Vitamin D - NCBI Bookshelf



4- Omega-3 fatty acids _ University of Maryland Medical Center

1- Vitamin D and Bone Health...

2- Iron deficiency anemia treatment...

3- Dietary Reference Intakes for...

4- Omega-3 fatty acids...

5- Effect of folic acid supplementation...

Ref 1 → Slide 7, 9.1, 9.2,

Ref 2 → Slide 10.1

Ref 3 → Slide 10.2, 10.3

Ref 4 → Slide 15, 16.1, 16.2, 18.1, 18.2

Ref 5 → Slide 24, 25, 26,

Common Questions & Tips



If your file size exceeds the limit of 1mb try changing the compression ratio of your jpg.



Don't include references and tags as part of your slide design. Attach them separately as explained on [page 17](#)



Use the full potential of REVO detailing features to make your sessions more exciting – include bottomless slides, videos & animated slides.



Your Product cover and detail aid cover design is the first visual element to show content/assigned products on REVO so designing an attractive one is important.



Each reference should be provided in a separate PDF file. Please do not collect all your references in one file.



Design your bottomless slides including the icon below in your design.





A world of data at your fingertips

You don't have to know coding,
just upload your files.
Ready, steady, go!



Export Files to Folders

AI empowered **E-detailing + CLM** Tablet interface

Quick | Smart | Powerful



REVO

Revo technology was developed by
the **Benchmark** Tech lab, a division of

Benchmark Labs

revosuite.com